{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:20:27Z","timestamp":1783527627076,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-026-06119-y","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:12:58Z","timestamp":1778663578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global inequities in biologic and targeted DMARD use in rheumatoid arthritis: cross-sectional data from the international COVAD-2 cohort"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4479-7678","authenticated-orcid":false,"given":"Nelly","family":"Ziade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4402-5034","authenticated-orcid":false,"given":"Ihsane","family":"Hmamouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Moussallem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bendy Lemon","family":"Salameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4372-2540","authenticated-orcid":false,"given":"Praggya","family":"Yaadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8748-898X","authenticated-orcid":false,"given":"Ashima","family":"Makol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-8768","authenticated-orcid":false,"given":"Marcin","family":"Milchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-1272","authenticated-orcid":false,"given":"Tsvetelina","family":"Velikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-3726","authenticated-orcid":false,"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-340X","authenticated-orcid":false,"given":"Vikas","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2753-2990","authenticated-orcid":false,"given":"Latika","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"COVAD Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"6119_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","volume":"402","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo A, Bathon JM, Emery P (2023) Rheumatoid arthritis. Lancet 402:2019\u20132033. https:\/\/doi.org\/10.1016\/S0140-6736(23)01525-8","journal-title":"Lancet"},{"key":"6119_CR2","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320:1360. https:\/\/doi.org\/10.1001\/jama.2018.13103","journal-title":"JAMA"},{"key":"6119_CR3","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1080\/1744666X.2022.2106970","volume":"18","author":"AI Venetsanopoulou","year":"2022","unstructured":"Venetsanopoulou AI, Alamanos Y, Voulgari PV, Drosos AA (2022) Epidemiology of rheumatoid arthritis: genetic and environmental influences. Expert Rev Clin Immunol 18:923\u2013931. https:\/\/doi.org\/10.1080\/1744666X.2022.2106970","journal-title":"Expert Rev Clin Immunol"},{"key":"6119_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1561926","volume":"16","author":"H Zeng","year":"2025","unstructured":"Zeng H, Yuan Z, Wu R, Huang Z (2025) Research progress on complications of rheumatoid arthritis. Front Immunol 16:1561926. https:\/\/doi.org\/10.3389\/fimmu.2025.1561926","journal-title":"Front Immunol"},{"key":"6119_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-082020","volume":"14","author":"J Feng","year":"2024","unstructured":"Feng J, Yu L, Fang Y et al (2024) Correlation between disease activity and patient-reported health-related quality of life in rheumatoid arthritis: a cross-sectional study. BMJ Open 14:e082020. https:\/\/doi.org\/10.1136\/bmjopen-2023-082020","journal-title":"BMJ Open"},{"key":"6119_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","volume":"74","author":"J Listing","year":"2015","unstructured":"Listing J, Kekow J, Manger B et al (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF\u03b1 inhibitors and rituximab. Ann Rheum Dis 74:415\u2013421. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204021","journal-title":"Ann Rheum Dis"},{"key":"6119_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejim.2023.06.013","volume":"115","author":"B Delcoigne","year":"2023","unstructured":"Delcoigne B, Provan SA, Kristianslund EK et al (2023) How does current disease activity in rheumatoid arthritis affect the short-term risk of acute coronary syndrome? A clinical register based study from Sweden and Norway. Eur J Intern Med 115:55\u201361. https:\/\/doi.org\/10.1016\/j.ejim.2023.06.013","journal-title":"Eur J Intern Med"},{"key":"6119_CR8","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1093\/rheumatology\/kead106","volume":"62","author":"RJ Black","year":"2023","unstructured":"Black RJ, Lester S, Tieu J et al (2023) Mortality estimates and excess mortality in rheumatoid arthritis. Rheumatology 62:3576\u20133583. https:\/\/doi.org\/10.1093\/rheumatology\/kead106","journal-title":"Rheumatology"},{"key":"6119_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"key":"6119_CR10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR et al (2021) 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 73:924\u2013939. https:\/\/doi.org\/10.1002\/acr.24596","journal-title":"Arthritis Care Res"},{"key":"6119_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070856","author":"P Brown","year":"2024","unstructured":"Brown P, Pratt AG, Hyrich KL (2024) Therapeutic advances in rheumatoid arthritis. BMJ. https:\/\/doi.org\/10.1136\/bmj-2022-070856","journal-title":"BMJ"},{"key":"6119_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10067-020-05227-9","volume":"40","author":"N Mena-V\u00e1zquez","year":"2021","unstructured":"Mena-V\u00e1zquez N, Godoy-Navarrete FJ, Manrique-Arija S et al (2021) Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis. Clin Rheumatol 40:133\u2013142. https:\/\/doi.org\/10.1007\/s10067-020-05227-9","journal-title":"Clin Rheumatol"},{"key":"6119_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003789","volume":"10","author":"T Rudi","year":"2024","unstructured":"Rudi T, Zietemann V, Meissner Y et al (2024) Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register. RMD Open 10:e003789. https:\/\/doi.org\/10.1136\/rmdopen-2023-003789","journal-title":"RMD Open"},{"key":"6119_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0325127","volume":"20","author":"J Li","year":"2025","unstructured":"Li J, Li Z, Hao C, Chen X (2025) Global burden and regional disparities of rheumatoid arthritis among the working-age population: a comprehensive analysis from 1990 to 2021 with projections to 2040. PLoS ONE 20:e0325127. https:\/\/doi.org\/10.1371\/journal.pone.0325127","journal-title":"PLoS ONE"},{"key":"6119_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-082966","volume":"14","author":"C Chen","year":"2024","unstructured":"Chen C, Shi Q, He W et al (2024) Global trends in the burden of rheumatoid arthritis by sociodemographic index: a joinpoint and age\u2013period\u2013cohort analysis based on the Global Burden of Disease Study 2019. BMJ Open 14:e082966. https:\/\/doi.org\/10.1136\/bmjopen-2023-082966","journal-title":"BMJ Open"},{"key":"6119_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK et al (2014) Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 73:198\u2013206. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202603","journal-title":"Ann Rheum Dis"},{"key":"6119_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkab081","volume":"5","author":"A Kaul","year":"2021","unstructured":"Kaul A, Mistry J, Iagnocco A et al (2021) Inequality of access to advanced therapies for patients with inflammatory arthritis: a postcode lottery? Rheumatol Adv Pract 5:rkab081. https:\/\/doi.org\/10.1093\/rap\/rkab081","journal-title":"Rheumatol Adv Pract"},{"key":"6119_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/OARRR.S493457","volume":"17","author":"G Wright","year":"2025","unstructured":"Wright G, Zueger P, Copley-Merriman C et al (2025) Health disparities in rheumatology in the United States. OARRR 17:1\u201312. https:\/\/doi.org\/10.2147\/OARRR.S493457","journal-title":"OARRR"},{"key":"6119_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3904\/kjim.2024.207","volume":"39","author":"OC Kwon","year":"2024","unstructured":"Kwon OC, Park M-C (2024) Inequalities in biologics utilization for rheumatoid arthritis according to socioeconomic status. Korean J Intern Med 39:545\u2013546. https:\/\/doi.org\/10.3904\/kjim.2024.207","journal-title":"Korean J Intern Med"},{"key":"6119_CR20","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s10067-024-06869-9","volume":"43","author":"J O\u2019Brien","year":"2024","unstructured":"O\u2019Brien J, Park SH, Blachley T et al (2024) Disparities in burden of disease in patients with rheumatoid arthritis across racial and ethnic groups. Clin Rheumatol 43:921\u2013927. https:\/\/doi.org\/10.1007\/s10067-024-06869-9","journal-title":"Clin Rheumatol"},{"key":"6119_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00296-023-05526-9","volume":"44","author":"S Asmar","year":"2024","unstructured":"Asmar S, Messaykeh J, Hilal N et al (2024) Drug persistence in patients with rheumatic and musculoskeletal diseases during a major economic crisis: results from a nationwide cross-sectional online survey. Rheumatol Int 44:725\u2013736. https:\/\/doi.org\/10.1007\/s00296-023-05526-9","journal-title":"Rheumatol Int"},{"key":"6119_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s41927-025-00501-2","volume":"9","author":"J Ainsworth","year":"2025","unstructured":"Ainsworth J, Bolic M, Ismail I et al (2025) Sociodemographic and economic barriers to initial specialist care for patients with rheumatoid arthritis: a scoping review. BMC Rheumatol 9:76. https:\/\/doi.org\/10.1186\/s41927-025-00501-2","journal-title":"BMC Rheumatol"},{"key":"6119_CR23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/acr.25192","volume":"77","author":"LW Desilet","year":"2025","unstructured":"Desilet LW, Pedro S, Katz P, Michaud K (2025) Urban and rural patterns of health care utilization among people with rheumatoid arthritis and osteoarthritis in a large US patient registry. Arthritis Care Res 77:412\u2013418. https:\/\/doi.org\/10.1002\/acr.25192","journal-title":"Arthritis Care Res"},{"key":"6119_CR24","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3899\/jrheum.2023-0103","volume":"50","author":"CY Lane","year":"2023","unstructured":"Lane CY, Lo D, Thoma LM et al (2023) Sociocultural and economic disparities in physical therapy utilization among insured older adults with rheumatoid arthritis. J Rheumatol 50:1414\u20131421. https:\/\/doi.org\/10.3899\/jrheum.2023-0103","journal-title":"J Rheumatol"},{"key":"6119_CR25","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s00296-022-05157-6","volume":"42","author":"ZZ Fazal","year":"2022","unstructured":"Fazal ZZ, Sen P, Joshi M et al (2022) COVAD survey 2 long-term outcomes: unmet need and protocol. Rheumatol Int 42:2151\u20132158. https:\/\/doi.org\/10.1007\/s00296-022-05157-6","journal-title":"Rheumatol Int"},{"key":"6119_CR26","unstructured":"UNDP Human Development Index (HDI). https:\/\/hdr.undp.org\/data-center\/human-development-index#\/indicies\/HDI. Accessed 3 Aug 2025"},{"key":"6119_CR27","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1093\/rheumatology\/kead149","volume":"62","author":"SS Ali","year":"2023","unstructured":"Ali SS, N R, Sen P et al (2023) Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: results from the COVAD study. Rheumatology 62:e263\u2013e268. https:\/\/doi.org\/10.1093\/rheumatology\/kead149","journal-title":"Rheumatology"},{"key":"6119_CR28","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.6.3.e34","volume":"6","author":"G Eysenbach","year":"2004","unstructured":"Eysenbach G (2004) Improving the quality of web surveys: the checklist for reporting results of internet e-surveys (CHERRIES). J Med Internet Res 6:e34. https:\/\/doi.org\/10.2196\/jmir.6.3.e34","journal-title":"J Med Internet Res"},{"key":"6119_CR29","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.rdc.2020.07.005","volume":"46","author":"C Barnabe","year":"2020","unstructured":"Barnabe C (2020) Disparities in rheumatoid arthritis care and health service solutions to equity. Rheum Dis Clin North Am 46:685\u2013692. https:\/\/doi.org\/10.1016\/j.rdc.2020.07.005","journal-title":"Rheum Dis Clin North Am"},{"key":"6119_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208240","volume":"13","author":"SR Dargham","year":"2018","unstructured":"Dargham SR, Zahirovic S, Hammoudeh M et al (2018) Epidemiology and treatment patterns of rheumatoid arthritis in a large cohort of Arab patients. PLoS ONE 13:e0208240. https:\/\/doi.org\/10.1371\/journal.pone.0208240","journal-title":"PLoS ONE"},{"key":"6119_CR31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3904\/kjim.2023.276","volume":"39","author":"HW Kim","year":"2024","unstructured":"Kim HW, Lee YJ, Ha Y-J et al (2024) Impact of socioeconomic status on biologics utilization in rheumatoid arthritis: revealing inequalities and healthcare efficiency. Korean J Intern Med 39:668\u2013679. https:\/\/doi.org\/10.3904\/kjim.2023.276","journal-title":"Korean J Intern Med"},{"key":"6119_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13075-026-03737-6","volume":"28","author":"X Huang","year":"2026","unstructured":"Huang X, Lin X, Dai Z, Fang K (2026) Global variation in the quality of care for rheumatoid arthritis and associated factors. Arthritis Res Ther 28:51. https:\/\/doi.org\/10.1186\/s13075-026-03737-6","journal-title":"Arthritis Res Ther"},{"key":"6119_CR33","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/acr.22244","volume":"66","author":"E Yelin","year":"2014","unstructured":"Yelin E, Tonner C, Kim SC et al (2014) Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: a longitudinal study. Arthritis Care Res 66:980\u2013989. https:\/\/doi.org\/10.1002\/acr.22244","journal-title":"Arthritis Care Res"},{"key":"6119_CR34","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3899\/jrheum.2025-0290","volume":"52","author":"AF Ara","year":"2025","unstructured":"Ara AF, Chenoweth M, Kadiyala S et al (2025) Racial and ethnic disparities in disease-modifying antirheumatic drug use among adults with rheumatoid arthritis in the United States. J Rheumatol 52:1316\u20131318. https:\/\/doi.org\/10.3899\/jrheum.2025-0290","journal-title":"J Rheumatol"},{"key":"6119_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/acr.25457","volume":"77","author":"A Naik","year":"2025","unstructured":"Naik A, Baraff A, Wysham KD et al (2025) Escalation to biologics after methotrexate among US veterans with rheumatoid arthritis grouped by rural versus urban areas. Arthritis Care Res 77:23\u201329. https:\/\/doi.org\/10.1002\/acr.25457","journal-title":"Arthritis Care Res"},{"key":"6119_CR36","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/S2665-9913(24)00221-2","volume":"7","author":"MD Russell","year":"2025","unstructured":"Russell MD, Gibson M, Zuckerman B et al (2025) Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study. Lancet Rheumatol 7:e44\u2013e54. https:\/\/doi.org\/10.1016\/S2665-9913(24)00221-2","journal-title":"Lancet Rheumatol"},{"key":"6119_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-023-00371-6","volume":"8","author":"L Zhu","year":"2024","unstructured":"Zhu L, Moreland LW, Ascherman D (2024) Cross-sectional association between social and demographic factors and disease activity in rheumatoid arthritis. BMC Rheumatol 8:2. https:\/\/doi.org\/10.1186\/s41927-023-00371-6","journal-title":"BMC Rheumatol"},{"key":"6119_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1706246","volume":"13","author":"Y Khan","year":"2026","unstructured":"Khan Y, Daraz U, Alsawalqa RO et al (2026) When poverty gets into your joints: exploring socioeconomic, environmental, and gendered determinants of rheumatoid arthritis in district Dir lower, Pakistan. Front Public Health 13:1706246. https:\/\/doi.org\/10.3389\/fpubh.2025.1706246","journal-title":"Front Public Health"},{"key":"6119_CR39","first-page":"477","volume":"35","author":"E Nikiphorou","year":"2017","unstructured":"Nikiphorou E, Galloway J, van Riel P et al (2017) The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey. Clin Exp Rheumatol 35:477\u2013483","journal-title":"Clin Exp Rheumatol"},{"key":"6119_CR40","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/rheumatology\/kead261","volume":"63","author":"SS Zhao","year":"2024","unstructured":"Zhao SS, Rogers K, Kearsley-Fleet L et al (2024) Socioeconomic deprivation is associated with reduced response and lower treatment persistence with TNF inhibitors in rheumatoid arthritis. Rheumatology 63:648\u2013656. https:\/\/doi.org\/10.1093\/rheumatology\/kead261","journal-title":"Rheumatology"},{"key":"6119_CR41","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/rheumatology\/kev395","volume":"55","author":"M Hifinger","year":"2016","unstructured":"Hifinger M, Putrik P, Ramiro S et al (2016) In rheumatoid arthritis, country of residence has an important influence on fatigue: results from the multinational COMORA study. Rheumatology 55:735\u2013744. https:\/\/doi.org\/10.1093\/rheumatology\/kev395","journal-title":"Rheumatology"},{"key":"6119_CR42","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1684\/mst.2012.0096","volume":"22","author":"S Ndongo","year":"2012","unstructured":"Ndongo S, Pouye A, Lekpa FK et al (2012) Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis. Med Sante Trop 22:385\u2013389. https:\/\/doi.org\/10.1684\/mst.2012.0096","journal-title":"Med Sante Trop"},{"key":"6119_CR43","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1136\/annrheumdis-2021-221965","volume":"81","author":"JW Bijlsma","year":"2022","unstructured":"Bijlsma JW (2022) EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients\u2019 questions. Ann Rheum Dis 81:786\u2013788. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221965","journal-title":"Ann Rheum Dis"},{"key":"6119_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105491","volume":"90","author":"M Doumen","year":"2023","unstructured":"Doumen M, Pazmino S, Bertrand D et al (2023) Glucocorticoids in rheumatoid arthritis: balancing benefits and harm by leveraging the therapeutic window of opportunity. Jt Bone Spine 90:105491. https:\/\/doi.org\/10.1016\/j.jbspin.2022.105491","journal-title":"Jt Bone Spine"},{"key":"6119_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NM, Welsing PM et al (2021) EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 80:31\u201335. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217344","journal-title":"Ann Rheum Dis"},{"key":"6119_CR46","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1093\/rheumatology\/kez081","volume":"58","author":"A Shin","year":"2019","unstructured":"Shin A, Shin S, Kim JH et al (2019) Association between socioeconomic status and comorbidities among patients with rheumatoid arthritis: results of a nationwide cross-sectional survey. Rheumatology (Oxford) 58:1617\u20131622. https:\/\/doi.org\/10.1093\/rheumatology\/kez081","journal-title":"Rheumatology (Oxford)"},{"key":"6119_CR47","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/annrheumdis-2017-212457","volume":"77","author":"E Nikiphorou","year":"2018","unstructured":"Nikiphorou E, van der Heijde D, Norton S et al (2018) Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study. Ann Rheum Dis 77:405\u2013411. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212457","journal-title":"Ann Rheum Dis"},{"key":"6119_CR48","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1136\/annrheumdis-2018-213289","volume":"77","author":"SA Bergstra","year":"2018","unstructured":"Bergstra SA, Branco JC, Vega-Morales D et al (2018) Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. Ann Rheum Dis 77:1413\u20131420. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213289","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06119-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06119-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06119-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:39:23Z","timestamp":1783525163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06119-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["6119"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06119-y","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was obtained from the Institutional Ethics Committee of the Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, and, where required, from the Institutional Review Boards of the participating countries. The current ancillary analysis received approval from the Ethics Committee of H\u00f4tel Dieu de France (Tfem2023-54).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Part of this study was presented as a poster at the EULAR 2024 meeting in Vienna, Austria (POS0069). This report was not copied or published elsewhere. In preparing this manuscript, the authors used Grammarly (Grammarly Inc., San Francisco, CA, USA) for grammar and language proofreading, and ChatGPT (OpenAI, San Francisco, CA, USA) to support medical writing, grammar proofreading, and the creation of figures. These tools were used under the full supervision and critical oversight of the authors, who take complete responsibility for the accuracy, integrity, and originality of the published work. No artificial intelligence tool was used for data analysis, interpretation of results, or the generation of scientific conclusions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"86"}}